Literature DB >> 20011281

Ulcerative proctitis.

Charles B Whitlow1.   

Abstract

Ulcerative proctitis is an idiopathic mucosal inflammatory disease involving only the rectum and is therefore an anatomically limited form of ulcerative colitis. Diagnosis is made based on clinical presentation, endoscopic appearance, and histopathology. Additionally, other etiologies of proctitis are excluded. The course of the disease is variable ranging from complete resolution to easily maintained remission to frequent relapses or refractory disease. Extension of inflammatory changes involving the proximal colon occurs in some cases. Rectal 5-aminosalicylic acid (5-ASA) or steroids are the initial treatments of choice with oral 5-ASA, sulfasalazine, or steroids used for treatment failures or patients unable to tolerate rectally administered drugs. Immunomodulators like azathioprine and 6-mercaptopurine have been used successfully in small groups of patients who have not responded to 5-ASA or steroids. Oral or rectal 5-ASA products maintain remission but long-term steroid use should be avoided. Rare cases may require surgical therapy.

Entities:  

Keywords:  5-ASA; Proctitis; hydrocortisone; ulcerative proctitis

Year:  2004        PMID: 20011281      PMCID: PMC2780078          DOI: 10.1055/s-2004-823067

Source DB:  PubMed          Journal:  Clin Colon Rectal Surg        ISSN: 1530-9681


  45 in total

1.  Comparative, open, randomized trial of the efficacy and tolerance of slow-release 5-ASA suppositories once daily versus conventional 5-ASA suppositories twice daily in the treatment of active cryptogenic proctitis: French Pentasa Study Group.

Authors:  P Marteau; C Florent
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

2.  Changes in extent of ulcerative colitis: a study on the course and prognostic factors.

Authors:  E Langholz; P Munkholm; M Davidsen; O H Nielsen; V Binder
Journal:  Scand J Gastroenterol       Date:  1996-03       Impact factor: 2.423

3.  Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy.

Authors:  J Brown; S Haines; I R Wilding
Journal:  Aliment Pharmacol Ther       Date:  1997-08       Impact factor: 8.171

4.  Acute ischemic proctitis. Report of six cases.

Authors:  R L Nelson; S Briley; J J Schuler; H Abcarian
Journal:  Dis Colon Rectum       Date:  1992-04       Impact factor: 4.585

5.  Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.

Authors:  S Ardizzone; P Doldo; T Ranzi; G C Sturniolo; L A Giglio; V Annese; A D'Arienzo; E Gaia; S Gullini; G Riegler; M Valentini; P Massa; M Del Piano; F Rossini; C S Guidetti; A Pera; R Greinwald; G Bianchi Porro
Journal:  Ital J Gastroenterol Hepatol       Date:  1999-11

6.  Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study.

Authors:  G d'Albasio; F Pacini; E Camarri; A Messori; G Trallori; A G Bonanomi; G Bardazzi; M Milla; S Ferrero; M Biagini; S Quaranta; A Amorosi
Journal:  Am J Gastroenterol       Date:  1997-07       Impact factor: 10.864

7.  Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories.

Authors:  C N Williams; G Haber; J A Aquino
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

8.  Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial.

Authors:  M Campieri; R De Franchis; G Bianchi Porro; T Ranzi; G Brunetti; L Barbara
Journal:  Scand J Gastroenterol       Date:  1990-07       Impact factor: 2.423

Review 9.  The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea.

Authors:  Brian W Hurley; Cuong C Nguyen
Journal:  Arch Intern Med       Date:  2002-10-28

10.  Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

Authors:  C S J Probert; S D Hearing; S Schreiber; T Kühbacher; S Ghosh; I D R Arnott; A Forbes
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

View more
  3 in total

1.  Investigation of HPLF-111624 in Modified Experimental Models of Ulcerative Proctitis and Anal Fissure in Rats.

Authors:  Mallappa Onkaramurthy; Mohammed Mukhram Azeemuddin; Mirza Rizwan Baig; Pavan Heggadadevanakote Kendaganna; Mohamed Rafiq; Uddagiri Venkanna Babu
Journal:  J Exp Pharmacol       Date:  2022-04-27

2.  Long-term outcomes of colectomy surgery among patients with ulcerative colitis.

Authors:  Carl Brown; Peter R Gibson; Ailsa Hart; Gilaad G Kaplan; Sumesh Kachroo; Qian Ding; Emily Hautamaki; Tao Fan; Christopher M Black; Xiaohan Hu; Kathleen Beusterien
Journal:  Springerplus       Date:  2015-10-05

Review 3.  Orphan patients with inflammatory bowel disease - when we treat beyond evidence.

Authors:  Giuseppe Privitera; Daniela Pugliese; Loris Riccardo Lopetuso; Franco Scaldaferri; Alfredo Papa; Gian Lodovico Rapaccini; Antonio Gasbarrini; Alessandro Armuzzi
Journal:  World J Gastroenterol       Date:  2021-12-21       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.